A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk

Prior treatment

• Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed \>1 year before screening)
• Have a prior or planned endoscopic procedure and/or device-based therapy for obesity (prior device-based therapy acceptable if device removal was more than 6 months prior to screening)
• Have had within 60 days prior to screening:
  • acute myocardial infarction
  • stroke
  • hospitalization for congestive heart failure, or
  • coronary, peripheral, or carotid artery revascularization procedure
• Have received treatment combining sulfonylurea and insulin within 90 days prior to screening

Other illness

• Have type 1 diabetes
• Have a history or diagnosis of New York Heart Association Functional Classification IV congestive heart failure

• Have type 2 diabetes
• Have a HbA1c value between ≥ 6.5% and ≤ 9.5% at screening
• Are on stable treatment with an unchanged dose of at least 1 and no more than 4 antihyperglycemic therapies for at least 90 days before screening
• Have an increased risk of cardiovascular events
• Have a BMI ≥ 25.0 kg/m2 at screening
• Have a stable body weight (\<5% body weight change) for 90 days prior to screening
• Have a history of at least one self-reported unsuccessful dietary effort to reduce body weight